As a result of the tender offer concluded on February 19, 2026, Taiyo Kosan Co., Ltd. acquired 41,803,599 shares of Hisamitsu Pharmaceutical Co., Inc. (61.81% voting rights), and is expected to become the parent company and principal shareholder.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4530","jir_company_name":"Hisamitsu Pharmaceutical Co., Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4530-20260220-01.pdf","jir_short_summary":"As a result of the tender offer concluded on February 19, 2026, Taiyo Kosan Co., Ltd. acquired 41,803,599 shares of Hisamitsu Pharmaceutical Co., Inc. (61.81% voting rights), and is expected to become the parent company and principal shareholder.","jir_summary":"### Overview of Tender Offer Results\nThe tender offer by Taiyo Kosan Co., Ltd. for the common shares and stock acquisition rights of Hisamitsu Pharmaceutical Co., Inc. ended on February 19, 2026. The number of shares tendered was 41,803,599, exceeding the lower limit of 41,119,400 shares planned for acquisition, resulting in the tender offer being successful. Consequently, as of February 27, 2026, Taiyo Kosan is expected to change status to parent company and principal shareholder with a voting rights ratio of 61.81%. The tender price is \u00a56,082 per common share, and the acquisition will be made in cash.\n\n### Future Outlook and Changes in Shareholder Composition\nFollowing the successful tender offer, Taiyo Kosan plans significant changes to Hisamitsu Pharmaceutical\u2019s shareholder structure with a view toward privatization. An extraordinary shareholders' meeting, including agenda items for share consolidation and amendments to the articles of incorporation, is scheduled for mid-April 2026. This is expected to lead to delisting from the stock exchange. Specific procedures and timing will be promptly announced after consultation with the offeror.","jir_financial_highlights":"Number of Shares Tendered: 41,803,599 shares (Established above the lower limit of 41,119,400 shares planned for acquisition)\nVoting Rights Ownership Ratio (post-acquisition): 61.81% (Significant increase from 2.51% before acquisition)\nTender Price (per common share): \u00a56,082 (Unknown)","jir_category":"","jir_hashtags":"#HisamitsuPharmaceutical, #TenderOffer, #TOB, #JapaneseStocks","jir_key_figures":"Number of shares tendered: 41,803,599 shares (above the lower limit of 41,119,400 shares planned for acquisition)\nVoting rights ownership after acquisition: 61.81% (2.51% before acquisition)\nTender price (per common share): \u00a56,082","jir_meta_title":"Hisamitsu Pharmaceutical Acquires 61.81% Voting Rights through Successful Tender Offer by Taiyo Kosan, Changing to Parent Company","jir_meta_description":"Through the tender offer concluded on February 19, 2026, Taiyo Kosan Co., Ltd. acquired 41,803,599 shares of Hisamitsu Pharmaceutical, reaching a voting rights ratio of 61.81%. Plans for privatization and delisting have also been indicated.","jir_og_title":"Hisamitsu Pharmaceutical Changes to Parent Company through Successful Tender Offer by Taiyo Kosan","jir_og_description":"Taiyo Kosan acquired 61.81% of Hisamitsu Pharmaceutical\u2019s shares, becoming the parent company and principal shareholder. Privatization and delisting are planned.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8125,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"tender_offer","footnotes":""},"sector":[],"importance":[],"class_list":["post-30317","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n